Novo Nordisk (NVO) Shares Fall 9% After Heart Drug Trial Fails

Novo Nordisk shares fell by as much as 10% following a statement regarding a late-stage trial of the heart drug ziltivekimab, which failed to significantly reduce major cardiovascular events when compared to a placebo. The company reported a decline of 8.6% in Copenhagen and 9.8% in premarket trading in the U.S. despite some biological effects observed. The chief scientific officer, Martin Holst Lange, affirmed the company's ongoing commitment to cardiovascular disease research. This news is important as it may impact investor confidence and stock performance for Novo Nordisk (NVO).